Last reviewed · How we verify
Tafamidis meglumine capsule
At a glance
| Generic name | Tafamidis meglumine capsule |
|---|---|
| Sponsor | Pfizer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Compare the Amount of Two Forms of Tafamidis in the Blood of Healthy Adults Under Fed Conditions (PHASE1)
- A Study to Learn About Tafamidis in Patients With Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in India
- Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy
- To Evaluate the Efficacy and Safety of Tafamidis Meglumine Soft Capsules in the Treatment of Adult Patients With Transthyretin Amyloid Polyneuropathy (PHASE4)
- A Study to Compare Two Forms of Study Medicine Tafamidis in the Blood in Healthy Adults (PHASE1)
- Vyndaqel Capsules Special Investigation (ATTR-CM)
- Vyndaqel Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
- Long-term Safety of Tafamidis in Subjects With Transthyretin Cardiomyopathy (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tafamidis meglumine capsule CI brief — competitive landscape report
- Tafamidis meglumine capsule updates RSS · CI watch RSS
- Pfizer portfolio CI